Purpose of the Procedure
- Determining patient eligibility for immunotherapy drugs.
- Predicting tumor response to immune checkpoint inhibitors.
- Optimizing the treatment plan to avoid ineffective therapies.
Book PD-L1 Expression Test in Saudi Arabia | Lahalak Medical Platform
The PD-L1 test is a critical step for cancer patients to determine the effectiveness of immunotherapy in fighting cancer cells, helping doctors design a personalized, high-precision treatment plan for better outcomes.
Scientific name: PD-L1 Expression Testing (IHC)
An immunohistochemical (IHC) assay that measures PD-L1 protein levels on cancer cells. It serves as a predictive biomarker to determine patient eligibility for checkpoint inhibitor therapies and optimize oncology treatment strategies.
Service type
Laboratory test (Histopathology)
Duration
3-5 business days
Fasting
Fasting is not required
Included Services
- Tissue block sample receipt
- Laboratory immunohistochemical analysis
- Detailed medical result report
Medical Service Information
Target Groups
- Patients with Non-Small Cell Lung Cancer (NSCLC).
- Individuals with urothelial or renal cell carcinoma.
- Patients with advanced malignancies exploring immunotherapy options.
Understanding the Results
- Positive Result: High protein expression suggests a better response to immunotherapy.
- Negative Result: Lower expression may indicate the need for alternative treatments.
- Scores like TPS or CPS help oncologists decide the specific drug dosage.
Conditions & Notices
- Previous biopsy report must be provided if available
- A recent tissue block sample is preferred for accurate results
Medical services you might also like
